PD04.04. Prognostic Significance of B7-H3 Expression in High-Risk Locally Advanced ESCC After Trimodality Therapy and Adjuvant Pembrolizumab: Post-Hoc Analysis
Esophageal Cancer: Molecular Biology/Pathology B7-H3 (CD276) is an immunoregulatory molecule and emerging therapeutic target. The prognostic value of B7-H3 expression in locally advanced esophageal squamous cell carcinoma (ESCC) treated with multimodality therapy plus adjuvant pembrolizumab was unclear. We...